Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252

Serina Therapeutics, Inc.

Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.
Preferred stock carries 8% cumulative annual dividend, paid in kind; convertible at $5.18 per common share.
Proceeds to support SER-252 (POZ-apomorphine) Phase 1 trial initiation in Q4 2025 for advanced Parkinson's.
Financing from strategic shareholders; conversion triggers include stock price doubling or $20M+ equity raise.

item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Serina Therapeutics, Inc.: Filed Certificate of Designations for Series A Convertible Preferred Stock, establishing rights, preferences, and limitations (effective 2025-04-10).

Change: charter amendment
Effective: 2025-04-10

Exact text from the filing

On April 10, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate of Designations") with the Secretary of State of the State of Delaware, which became effective upon filing.

View on SEC.gov

Browse all governance changes →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-25-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.